Review on clinical trials of targeted treatments in malignant mesothelioma

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 1-15

  Jakobsen, Jan Nyrop ^a,b   Sørensen, Jens Benn ^a  

^a Finsencentre ^*  (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Malignant mesothelioma; Malignant pleural mesothelioma; Targeted treatments; Tyrosine kinase inhibitors

Indexed keywords

AMATUXIMAB; BELINOSTAT; BEVACIZUMAB; CEDIRANIB; CISPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MESOTHELIN; PAZOPANIB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RANPIRNASE; RIBONUCLEASE; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VORINOSTAT;

ADD ON THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; DRUG RESPONSE; HUMAN; INFORMATION RETRIEVAL; MALIGNANT MESOTHELIOMA; MEDLINE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; PLEURAL NEOPLASMS;

EID: 79955562300     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1655-3     Document Type: Short Survey

References (104)

1. Steele JPC, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT et al (2005) Prognostic factors in mesothelioma. Lung Cancer 49(Suppl 1):S49-S52 (Pubitemid 40798846)
2. Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 52(6):507-512 (Pubitemid 27298500)
3. Vogelzang NJ, Porta C, Mutti L (2005) New agents in the management of advanced mesothelioma. Semin Oncol 32(3):336-350 (Pubitemid 40834490)
4. Sørensen JB, Frank H, Palshof T (2008) Cisplatin and vinorel-bine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 99(1):44-50 (Pubitemid 351920221)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636-2644 (Pubitemid 46606305)
6. Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36(1):24-32
7. Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Waller DA et al (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85(6):863-868 (Pubitemid 33010554)
8. Filiberti R, Marroni P, Neri M, Ardizzoni A, Betta PG, Cafferata MA et al (2005) Serum PDGF-AB in pleural mesothelioma. Tumour Biol 26(5):221-226 (Pubitemid 41243222)
9. Arber DA, Tamayo R, Weiss LM (1998) Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 29(5):498-504 (Pubitemid 28213470)
10. Millward M, Parnis F, Byrne M, Powell A, Dunleavey R, Lynch K et al (2003) Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Am J Clin Oncol 22:912
11. Mathy A, Baas P, Dalesio O, van Zandwijk N (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50(1):83-86 (Pubitemid 41297473)
12. Porta C, Mutti L, Tassi G (2007) Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 59(1):149-150 (Pubitemid 44796113)
13. Villano J, Husain A, Stadler M, Hanson L, Vogelzang N, Kindler H et al (2004) A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 22:14
14. Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S et al (2007) Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 62(8):690-695 (Pubitemid 47235011)
15. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62(19):5476-5484
16. Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF et al (2007) Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 13(19):5876-5882 (Pubitemid 47583914)
17. Cisplatin, pemetrexed, and imatinib mesylate in malignant mesothelioma. http://www.clinicaltrials.gov
18. A Phase II study of the association of Glivec® Plus Gemzar® in patients with unresectable, refractory, malignant mesothelioma. http://www.clinicaltrials.gov
19. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S et al (2007) Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-1972 (Pubitemid 47052486)
20. Tsao A, Mistuba I, Mehren J (2010) Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. Am J Clin Oncol 25:15
21. Dudek A, Pang H, Kratzke A (2010) A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma. J Natl Cancer Inst 28:15
22. Dasatinib in treating patients with previously treated malignant mesothelioma. http://www.clinicaltrials.gov
23. Irshad S, Popat S, Shah R (2010) A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET. J Natl Cancer Inst 28:15
24. Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R et al (2010) A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 5(10):1655-1661
25. Novak A, Millward M, Francis R (2010) Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma. J Clin Oncol 28:15
26. Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3-S8
27. Destro A, Ceresoli G, Falleni M (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 51:207-215
28. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D et al (2005) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11(6):2300-2304 (Pubitemid 40490190)
29. Lee C, Anderson H, Martins H (2008) A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM). J Clin Oncol 26:15
30. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB et al (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25(17):2406-2413
31. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J et al (2008) Erlotinib plus bevacizumab in previously treated patientswith malignant pleural mesothelioma. Cancer 113(4):808-814
32. Cortese J, Gowda A, Wali A, Eliason J, Pass H, Everson R et al (2006) Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignantmesothelioma. Int J Cancer 118(2):521-522 (Pubitemid 41779097)
33. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81(1):54-61 (Pubitemid 29415491)
34. Dowell J, Kindler H (2005) Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 19:1137-1145 (Pubitemid 41736047)
35. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S et al (2010) Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 5(4):479-483
36. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193(4):468-475 (Pubitemid 32266815)
37. Karrison T, Kindler HL, Gandara DR (2007) S374 Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma. J Thorac Oncol 2:8
38. Dowell J, Gerber D, Dunphy F (2010) Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients (pts) with untreated malignant mesothelioma. J Clin Oncol 28:15
39. Zalcman G, Margery J, Scherpereel A (2010) IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 28:15
40. Jahan T, Gu L, Wang X (2006) Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 24(18):7081
41. Mitchell CL, O'Connor JPB, Roberts C, Watson Y, Jackson A, Cheung S, et al. (2010) A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol
42. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U et al (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(21):3045-3054 (Pubitemid 47218051)
43. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C et al (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27(33):5601-5606
44. Garland L, Chansky K, Wosniak A (2009) A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 27:15
45. Pemetrexed disodium and cisplatin with or without cediranib maleate in treating patients with malignant pleural mesothelioma. http://www. clinicaltrials.gov
46. Kindler H, Vogelzang J, Chien K (2001) SU5416 in malignant mesothelioma: a University of Chicago consortium study. J Clin Oncol 20:341
47. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11(7):753-764 (Pubitemid 44157563)
48. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N et al (2005) Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48(2):291-296
49. Pavlakis N, Abraham R, Harvie R (2003) Thalidomide alone or in combination with cisplatin/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studies. Lung Cancer 41(2):11
50. MATES: Maintenance Thalidomide in Mesothelioma Patients. A phase III trial of anti-angiogenic agent Thalidomide in patients with malignant pleural mesothelioma after first line chemotherapy. http://www.anzctr.org.au/ ACTRN12609000141246.aspx
51. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M et al (2006) Cellular and molecular parameters of mesothelioma. J Cell Biochem 98(4):723-734 (Pubitemid 43993391)
52. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A et al (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40):6080-6089 (Pubitemid 43080058)
53. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novelmTORinhibitor, in patients with cancer. J Clin Oncol 22(12):2336-2347 (Pubitemid 41115390)
54. Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ (2010) Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 139(5):1233-1240
55. Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity. http://www. clinicaltrials.gov
56. Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery. http://www.clinicaltrials.gov
57. Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I et al (1992) Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16(3):259-268
58. Shaw DR, Muminova ZE, Strong TV (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10(24):8751 (author reply 8752)
59. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93(1):136-140 (Pubitemid 26041483)
60. Hassan R, Bera T, Pastan I (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10(12 Pt 1):3937-3942 (Pubitemid 38812466)
61. Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC et al (2010) Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 68(3):455-459
62. Laheru D, Cohen J, PhillipsM(2008) A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer. J Clin Oncol 26:15
63. An Efficacy Study of MORAb-009 Amatuximab in Subjects With Pleural Mesothelioma. http://www.clinicaltrials.gov
64. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H et al (2002) Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20(1):274-281 (Pubitemid 34032621)
65. Reck M, Krzakowski M, Jassem J (2009) Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). J Clin Oncol 27:15
66. Mittelman A, Puccio C, Gafney E, Coombe N, Singh B, Wood D et al (1992) A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 10(3):183-190
67. Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Takita H et al (1989) A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 23(3):186-191 (Pubitemid 19076605)
68. Lejeune FJ, Liénard D, Matter M, Rüegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6
69. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM et al (2010) Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol 28(15):2604-2611
70. NGR015: Study in Second Line for Patient with Advanced Malignant Pleural Mesothelioma Pretreated with Pemetrexed. http://www.clinicaltrials.gov
71. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137-168 (Pubitemid 39140958)
72. Frew AJ, Johnstone RW, Bolden JE (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280(2):125-133
73. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17):3923-3931 (Pubitemid 46218695)
74. Ramalingam SS, Parise RA, Ramanathan RK, Ramananthan RK, Lagattuta TF, Musguire LA et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13(12):3605-3610 (Pubitemid 46955122)
75. Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1). http://www.clinicaltrials.gov
76. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M et al (2009) Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4(1):97-101
77. Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y et al (2011) Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 37(1):129-135
78. Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ et al (2011) Phase I Studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res
79. Kai K, D'Costa S, Sills RC, Kim Y (2009) Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 278(1):49-55
80. Pazopanib in Treating Patients With Malignant Pleural Mesothelioma. http://www.clinicaltrials.gov
81. Axitinib in Malignant Mesothelioma (N08CPA). http://www.clinicaltrials. gov
82. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D et al (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13(19):5942-5951 (Pubitemid 47583922)
83. Bortezomib in Treating Patients With Malignant Pleural Mesothelioma. http://www.clinicaltrials.gov
84. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL et al (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61(4):549-558
85. Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma. http://www.clinicaltrials.gov
86. A Study of Cetuximab Combined With Cisplatin or Carboplatin/ Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. (MesoMab). http://www.clinicaltrials.gov
87. Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide. http://www.clinicaltrials.gov
88. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550 (Pubitemid 44917502)
89. Johnson D, Fehrenbacher L, Novotny W (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191 (Pubitemid 41095154)
90. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342 (Pubitemid 38702844)
91. Frederick PJ, Straughn JM, Alvarez RD, Buchsbaum DJ (2009) Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 113(3):384-390
92. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676
93. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91(3):329-336
94. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388
95. Whitehead J (2004) Stopping clinical trials by design. Nat Rev Drug Discov 3(11):973-977
96. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480 (Pubitemid 34879334)
97. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279(30):31655-31663 (Pubitemid 39037836)
98. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2):257-260 (Pubitemid 38262625)
99. Alavi A (2010) Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol [Epub ahead of print]
100. Federal Drug Administration (2007) Guidance for industry. Clinical trials endpoints for the approval of cancer drugs and biologics. UD Department of Health and Human Services, Rockville
101. Di Leo A, Bleiberg H, Buyse M (2003) Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 21(10):2045-2047
102. Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A et al (2006) Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma - the EORTC Lung Cancer Group. J Clin Oncol 24(19):3007-3012 (Pubitemid 46638933)
103. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97(12):880-887 (Pubitemid 41417939)
104. Bang Y, Kwak L, Shaw A (2010) Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28:18